Double Blind, Placebo-controlled Trial for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending and Multiple Oral Doses of GLPG0259 in Healthy Subjects

Further study details as provided by Galapagos NV:

Primary Outcome Measures:

Safety and tolerability of single and multiple dosing [ Time Frame: up to 10 days postdose ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Pharmacokinetics of single and repeated doses [ Time Frame: up to 10 days postdose ] [ Designated as safety issue: No ]

Exploratory evaluation of TNF-alpha and IL6 in whole blood [ Time Frame: up to 12 hours postdose ] [ Designated as safety issue: No ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00905138